In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii

Journal of Antimicrobial Chemotherapy

Volumn 62, Issue 2, 2008, Pages 422-423

  Capone, Alessandro ^a   D'Arezzo, Silvia ^a   Visca, Paolo ^a,b   Petrosillo, Nicola ^a  

^a NATIONAL INSTITUTE FOR INFECTIOUS DISEASES L SPALLANZANI   (Italy)

^b ROMA TRE UNIVERSITY   (Italy)

Author keywords

Antibiotics; Etracyclines; GAR 936; Lycylcyclines

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DOXYCYCLINE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; TETRACYCLINE; TIGECYCLINE;

ACINETOBACTER BAUMANNII; AMPLIFIED RIBOSOMAL DNA RESTRICTION ANALYSIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATE; BROTH DILUTION; DISK DIFFUSION; HUMAN; IN VITRO STUDY; INTENSIVE CARE UNIT; ITALY; LETTER; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN;

ACINETOBACTER BAUMANNII; ACINETOBACTER INFECTIONS; ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE;

EID: 47249114954     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn172     Document Type: Letter

References (9)

1. Dijkshoom L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5: 939-51.
2. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005; 56: 611-4.
3. Henwood CJ, Gatward T, Warner M et al. Antibiotic resistance among clinical isolates of Acinetobacter in the UK, and in vitro evaluation of tigecycline (GAR-936). J Antimicrob Chemother 2002; 49: 479-87.
4. Navon-Venezia S, Leavitt A, Carmeli Y. High tigecycline resistance in multidrug-resistant Acinetobacter baumannii. J Antimicrob Chemother 2007; 59: 772-4.
5. Seifert H, Stefanik D, Wisplinghoff H. Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother 2006; 58: 1099-100.
6. Scheetz MH, Qi C, Warren JR et al. In vitro activities of various antimicrobials alone and in combination with tigecycline against carbapenem-intermediate or -resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51: 1621-6.
7. Mezzatesta ML, Trovato G, Gona F et al. In vitro activity of tigecycline and comparators against carbapenem-susceptible and resistant Acinetobacter baumannii clinical isolates in Italy. Ann Clin Microbiol Antimicrob 2008; 7: 4.
8. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39: 183-90.
9. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 2006; 43 Suppl 2: S43-8.